The global Antisense & RNAi Therapeutics market is projected to grow from US$ 1002.6 million in 2023 to US$ 1287.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period.

Antisense & RNAi Therapeutics Market

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".

Market Analysis and Insights: Global Antisense & RNAi Therapeutics Market

North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

Report Includes

This report presents an overview of global market for Antisense & RNAi Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Antisense & RNAi Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antisense & RNAi Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense & RNAi Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Antisense & RNAi Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Antisense & RNAi Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Arbutus Biopharma Ltd., Silence Therapeutics, Bio-Path Holdings Inc., Calando Pharmaceuticals, ICo Therapeutics and Quark Pharmaceuticals, etc.

Scope of Antisense & RNAi Therapeutics Market Report

Report Metric	Details
Report Name	Antisense & RNAi Therapeutics Market
Accounted market size in 2023	US$ 1002.6 million
Forecasted market size in 2029	US$ 1287.2 million
CAGR	4.3
Base Year	2023
Forecasted years	2023 - 2029
Segment by Type	RNA Interference SiRNA MiRNA Antisense RNA
Segment by Application	Oncology Cardiovascular Renal Neurodegenerative Respiratory Genetic Infectious Diseases
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Arbutus Biopharma Ltd., Silence Therapeutics, Bio-Path Holdings Inc., Calando Pharmaceuticals, ICo Therapeutics, Quark Pharmaceuticals, Rexhan Pharmaceuticals, Biomarin/Prosensa, Regulus Therapeutics, Rxi Pharmaceuticals, Silenseed, Dicerna Pharmaceuticals, Sirnaomics Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antisense & RNAi Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense & RNAi Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense & RNAi Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Antisense & RNAi Therapeutics Market growing?

Ans: The Antisense & RNAi Therapeutics Market witnessing a CAGR of 4.3 during the forecast period 2023-2029.

What is the Antisense & RNAi Therapeutics Market size in 2029?

Ans: The global Antisense & RNAi Therapeutics market is projected to grow from US$ 1002.6 million in 2023 to US$ 1287.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period.

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029

1.2.2 RNA Interference

1.2.3 SiRNA

1.2.4 MiRNA

1.2.5 Antisense RNA

1.3 Market by Application

1.3.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029

1.3.2 Oncology

1.3.3 Cardiovascular

1.3.4 Renal

1.3.5 Neurodegenerative

1.3.6 Respiratory

1.3.7 Genetic

1.3.8 Infectious Diseases

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antisense & RNAi Therapeutics Market Perspective (2018-2029)

2.2 Global Antisense & RNAi Therapeutics Growth Trends by Region

2.2.1 Antisense & RNAi Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Antisense & RNAi Therapeutics Historic Market Size by Region (2018-2023)

2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Region (2024-2029)

2.3 Antisense & RNAi Therapeutics Market Dynamics

2.3.1 Antisense & RNAi Therapeutics Industry Trends

2.3.2 Antisense & RNAi Therapeutics Market Drivers

2.3.3 Antisense & RNAi Therapeutics Market Challenges

2.3.4 Antisense & RNAi Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Antisense & RNAi Therapeutics by Players

3.1.1 Global Antisense & RNAi Therapeutics Revenue by Players (2018-2023)

3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2018-2023)

3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Antisense & RNAi Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023

3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio

3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2022

3.5 Global Key Players of Antisense & RNAi Therapeutics Head office and Area Served

3.6 Global Key Players of Antisense & RNAi Therapeutics, Product and Application

3.7 Global Key Players of Antisense & RNAi Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antisense & RNAi Therapeutics Breakdown Data by Type

4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2018-2023)

4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2024-2029)

5 Antisense & RNAi Therapeutics Breakdown Data by Application

5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2018-2023)

5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2024-2029)

6 North America

6.1 North America Antisense & RNAi Therapeutics Market Size (2018-2029)

6.2 North America Antisense & RNAi Therapeutics Market Size by Type

6.2.1 North America Antisense & RNAi Therapeutics Market Size by Type (2018-2023)

6.2.2 North America Antisense & RNAi Therapeutics Market Size by Type (2024-2029)

6.2.3 North America Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

6.3 North America Antisense & RNAi Therapeutics Market Size by Application

6.3.1 North America Antisense & RNAi Therapeutics Market Size by Application (2018-2023)

6.3.2 North America Antisense & RNAi Therapeutics Market Size by Application (2024-2029)

6.3.3 North America Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

6.4 North America Antisense & RNAi Therapeutics Market Size by Country

6.4.1 North America Antisense & RNAi Therapeutics Market Size by Country: 2018 VS 2022 VS 2029

6.4.2 North America Antisense & RNAi Therapeutics Market Size by Country (2018-2023)

6.4.3 North America Antisense & RNAi Therapeutics Market Size by Country (2024-2029)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Antisense & RNAi Therapeutics Market Size (2018-2029)

7.2 Europe Antisense & RNAi Therapeutics Market Size by Type

7.2.1 Europe Antisense & RNAi Therapeutics Market Size by Type (2018-2023)

7.2.2 Europe Antisense & RNAi Therapeutics Market Size by Type (2024-2029)

7.2.3 Europe Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

7.3 Europe Antisense & RNAi Therapeutics Market Size by Application

7.3.1 Europe Antisense & RNAi Therapeutics Market Size by Application (2018-2023)

7.3.2 Europe Antisense & RNAi Therapeutics Market Size by Application (2024-2029)

7.3.3 Europe Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

7.4 Europe Antisense & RNAi Therapeutics Market Size by Country

7.4.1 Europe Antisense & RNAi Therapeutics Market Size by Country: 2018 VS 2022 VS 2029

7.4.2 Europe Antisense & RNAi Therapeutics Market Size by Country (2018-2023)

7.4.3 Europe Antisense & RNAi Therapeutics Market Size by Country (2024-2029)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Antisense & RNAi Therapeutics Market Size (2018-2029)

8.2 China Antisense & RNAi Therapeutics Market Size by Type

8.2.1 China Antisense & RNAi Therapeutics Market Size by Type (2018-2023)

8.2.2 China Antisense & RNAi Therapeutics Market Size by Type (2024-2029)

8.2.3 China Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

8.3 China Antisense & RNAi Therapeutics Market Size by Application

8.3.1 China Antisense & RNAi Therapeutics Market Size by Application (2018-2023)

8.3.2 China Antisense & RNAi Therapeutics Market Size by Application (2024-2029)

8.3.3 China Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

9 Asia (excluding China)

9.1 Asia Antisense & RNAi Therapeutics Market Size (2018-2029)

9.2 Asia Antisense & RNAi Therapeutics Market Size by Type

9.2.1 Asia Antisense & RNAi Therapeutics Market Size by Type (2018-2023)

9.2.2 Asia Antisense & RNAi Therapeutics Market Size by Type (2024-2029)

9.2.3 Asia Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

9.3 Asia Antisense & RNAi Therapeutics Market Size by Application

9.3.1 Asia Antisense & RNAi Therapeutics Market Size by Application (2018-2023)

9.3.2 Asia Antisense & RNAi Therapeutics Market Size by Application (2024-2029)

9.3.3 Asia Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

9.4 Asia Antisense & RNAi Therapeutics Market Size by Region

9.4.1 Asia Antisense & RNAi Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

9.4.2 Asia Antisense & RNAi Therapeutics Market Size by Region (2018-2023)

9.4.3 Asia Antisense & RNAi Therapeutics Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Type

10.2.1 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Application

10.3.1 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country

10.4.1 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country (2024-2029)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Glaxo Smith Kline

11.1.1 Glaxo Smith Kline Company Details

11.1.2 Glaxo Smith Kline Business Overview

11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction

11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.1.5 Glaxo Smith Kline Recent Developments

11.2 Sanofi Aventis / Genzyme

11.2.1 Sanofi Aventis / Genzyme Company Details

11.2.2 Sanofi Aventis / Genzyme Business Overview

11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction

11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.2.5 Sanofi Aventis / Genzyme Recent Developments

11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals

11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details

11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview

11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Developments

11.4 Arbutus Biopharma Ltd.

11.4.1 Arbutus Biopharma Ltd. Company Details

11.4.2 Arbutus Biopharma Ltd. Business Overview

11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction

11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.4.5 Arbutus Biopharma Ltd. Recent Developments

11.5 Silence Therapeutics

11.5.1 Silence Therapeutics Company Details

11.5.2 Silence Therapeutics Business Overview

11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction

11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.5.5 Silence Therapeutics Recent Developments

11.6 Bio-Path Holdings Inc.

11.6.1 Bio-Path Holdings Inc. Company Details

11.6.2 Bio-Path Holdings Inc. Business Overview

11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction

11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.6.5 Bio-Path Holdings Inc. Recent Developments

11.7 Calando Pharmaceuticals

11.7.1 Calando Pharmaceuticals Company Details

11.7.2 Calando Pharmaceuticals Business Overview

11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.7.5 Calando Pharmaceuticals Recent Developments

11.8 ICo Therapeutics

11.8.1 ICo Therapeutics Company Details

11.8.2 ICo Therapeutics Business Overview

11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction

11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.8.5 ICo Therapeutics Recent Developments

11.9 Quark Pharmaceuticals

11.9.1 Quark Pharmaceuticals Company Details

11.9.2 Quark Pharmaceuticals Business Overview

11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.9.5 Quark Pharmaceuticals Recent Developments

11.10 Rexhan Pharmaceuticals

11.10.1 Rexhan Pharmaceuticals Company Details

11.10.2 Rexhan Pharmaceuticals Business Overview

11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.10.5 Rexhan Pharmaceuticals Recent Developments

11.11 Biomarin/Prosensa

11.11.1 Biomarin/Prosensa Company Details

11.11.2 Biomarin/Prosensa Business Overview

11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction

11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.11.5 Biomarin/Prosensa Recent Developments

11.12 Regulus Therapeutics

11.12.1 Regulus Therapeutics Company Details

11.12.2 Regulus Therapeutics Business Overview

11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction

11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.12.5 Regulus Therapeutics Recent Developments

11.13 Rxi Pharmaceuticals

11.13.1 Rxi Pharmaceuticals Company Details

11.13.2 Rxi Pharmaceuticals Business Overview

11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.13.5 Rxi Pharmaceuticals Recent Developments

11.14 Silenseed

11.14.1 Silenseed Company Details

11.14.2 Silenseed Business Overview

11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction

11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.14.5 Silenseed Recent Developments

11.15 Dicerna Pharmaceuticals

11.15.1 Dicerna Pharmaceuticals Company Details

11.15.2 Dicerna Pharmaceuticals Business Overview

11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction

11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.15.5 Dicerna Pharmaceuticals Recent Developments

11.16 Sirnaomics Inc.

11.16.1 Sirnaomics Inc. Company Details

11.16.2 Sirnaomics Inc. Business Overview

11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction

11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023)

11.16.5 Sirnaomics Inc. Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Silence Therapeutics

Sirnaomics

Glaxo Smith Kline

Sanofi Aventis / Genzyme

Isis Pharmaceuticals/ Ionis Pharmaceuticals

Arbutus Biopharma Ltd.

Bio-Path Holdings Inc.

Calando Pharmaceuticals

iCo Therapeutics

Quark Pharmaceuticals

Rexhan Pharmaceuticals

Dicerna Pharmaceuticals

List of Tables

Table 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of RNA Interference

Table 3. Key Players of SiRNA

Table 4. Key Players of MiRNA

Table 5. Key Players of Antisense RNA

Table 6. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029

Table 7. Global Antisense & RNAi Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 8. Global Antisense & RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million)

Table 9. Global Antisense & RNAi Therapeutics Market Share by Region (2018-2023)

Table 10. Global Antisense & RNAi Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 11. Global Antisense & RNAi Therapeutics Market Share by Region (2024-2029)

Table 12. Antisense & RNAi Therapeutics Market Trends

Table 13. Antisense & RNAi Therapeutics Market Drivers

Table 14. Antisense & RNAi Therapeutics Market Challenges

Table 15. Antisense & RNAi Therapeutics Market Restraints

Table 16. Global Antisense & RNAi Therapeutics Revenue by Players (2018-2023) & (US$ Million)

Table 17. Global Antisense & RNAi Therapeutics Revenue Share by Players (2018-2023)

Table 18. Global Top Antisense & RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2022)

Table 19. Global Antisense & RNAi Therapeutics Industry Ranking 2021 VS 2022 VS 2023

Table 20. Global 5 Largest Players Market Share by Antisense & RNAi Therapeutics Revenue (CR5 and HHI) & (2018-2023)

Table 21. Global Key Players of Antisense & RNAi Therapeutics, Headquarters and Area Served

Table 22. Global Key Players of Antisense & RNAi Therapeutics, Product and Application

Table 23. Global Key Players of Antisense & RNAi Therapeutics, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 26. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2018-2023)

Table 27. Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 28. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2024-2029)

Table 29. Global Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 30. Global Antisense & RNAi Therapeutics Revenue Share by Application (2018-2023)

Table 31. Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 32. Global Antisense & RNAi Therapeutics Revenue Share by Application (2024-2029)

Table 33. North America Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 34. North America Antisense & RNAi Therapeutics Market Size by Type (2024-2029) & (US$ Million)

Table 35. North America Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 36. North America Antisense & RNAi Therapeutics Market Size by Application (2024-2029) & (US$ Million)

Table 37. North America Antisense & RNAi Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 38. North America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)

Table 39. North America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)

Table 40. Europe Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 41. Europe Antisense & RNAi Therapeutics Market Size by Type (2024-2029) & (US$ Million)

Table 42. Europe Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 43. Europe Antisense & RNAi Therapeutics Market Size by Application (2024-2029) & (US$ Million)

Table 44. Europe Antisense & RNAi Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 45. Europe Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)

Table 46. Europe Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)

Table 47. China Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 48. China Antisense & RNAi Therapeutics Market Size by Type (2024-2029) & (US$ Million)

Table 49. China Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 50. China Antisense & RNAi Therapeutics Market Size by Application (2024-2029) & (US$ Million)

Table 51. Asia Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 52. Asia Antisense & RNAi Therapeutics Market Size by Type (2024-2029) & (US$ Million)

Table 53. Asia Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 54. Asia Antisense & RNAi Therapeutics Market Size by Application (2024-2029) & (US$ Million)

Table 55. Asia Antisense & RNAi Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 56. Asia Antisense & RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million)

Table 57. Asia Antisense & RNAi Therapeutics Market Size by Region (2024-2029) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Type (2024-2029) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Application (2024-2029) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029

Table 63. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)

Table 64. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)

Table 65. Glaxo Smith Kline Company Details

Table 66. Glaxo Smith Kline Business Overview

Table 67. Glaxo Smith Kline Antisense & RNAi Therapeutics Product

Table 68. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 69. Glaxo Smith Kline Recent Developments

Table 70. Sanofi Aventis / Genzyme Company Details

Table 71. Sanofi Aventis / Genzyme Business Overview

Table 72. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product

Table 73. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 74. Sanofi Aventis / Genzyme Recent Developments

Table 75. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details

Table 76. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview

Table 77. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 78. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 79. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Developments

Table 80. Arbutus Biopharma Ltd. Company Details

Table 81. Arbutus Biopharma Ltd. Business Overview

Table 82. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product

Table 83. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 84. Arbutus Biopharma Ltd. Recent Developments

Table 85. Silence Therapeutics Company Details

Table 86. Silence Therapeutics Business Overview

Table 87. Silence Therapeutics Antisense & RNAi Therapeutics Product

Table 88. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 89. Silence Therapeutics Recent Developments

Table 90. Bio-Path Holdings Inc. Company Details

Table 91. Bio-Path Holdings Inc. Business Overview

Table 92. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product

Table 93. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 94. Bio-Path Holdings Inc. Recent Developments

Table 95. Calando Pharmaceuticals Company Details

Table 96. Calando Pharmaceuticals Business Overview

Table 97. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 98. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 99. Calando Pharmaceuticals Recent Developments

Table 100. ICo Therapeutics Company Details

Table 101. ICo Therapeutics Business Overview

Table 102. ICo Therapeutics Antisense & RNAi Therapeutics Product

Table 103. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 104. ICo Therapeutics Recent Developments

Table 105. Quark Pharmaceuticals Company Details

Table 106. Quark Pharmaceuticals Business Overview

Table 107. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 108. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 109. Quark Pharmaceuticals Recent Developments

Table 110. Rexhan Pharmaceuticals Company Details

Table 111. Rexhan Pharmaceuticals Business Overview

Table 112. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 113. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 114. Rexhan Pharmaceuticals Recent Developments

Table 115. Biomarin/Prosensa Company Details

Table 116. Biomarin/Prosensa Business Overview

Table 117. Biomarin/Prosensa Antisense & RNAi Therapeutics Product

Table 118. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 119. Biomarin/Prosensa Recent Developments

Table 120. Regulus Therapeutics Company Details

Table 121. Regulus Therapeutics Business Overview

Table 122. Regulus Therapeutics Antisense & RNAi Therapeutics Product

Table 123. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 124. Regulus Therapeutics Recent Developments

Table 125. Rxi Pharmaceuticals Company Details

Table 126. Rxi Pharmaceuticals Business Overview

Table 127. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 128. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 129. Rxi Pharmaceuticals Recent Developments

Table 130. Silenseed Company Details

Table 131. Silenseed Business Overview

Table 132. Silenseed Antisense & RNAi Therapeutics Product

Table 133. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 134. Silenseed Recent Developments

Table 135. Dicerna Pharmaceuticals Company Details

Table 136. Dicerna Pharmaceuticals Business Overview

Table 137. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product

Table 138. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 139. Dicerna Pharmaceuticals Recent Developments

Table 140. Sirnaomics Inc. Company Details

Table 141. Sirnaomics Inc. Business Overview

Table 142. Sirnaomics Inc. Antisense & RNAi Therapeutics Product

Table 143. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million)

Table 144. Sirnaomics Inc. Recent Developments

Table 145. Research Programs/Design for This Report

Table 146. Key Data Information from Secondary Sources

Table 147. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)

Figure 2. Global Antisense & RNAi Therapeutics Market Share by Type: 2022 VS 2029

Figure 3. RNA Interference Features

Figure 4. SiRNA Features

Figure 5. MiRNA Features

Figure 6. Antisense RNA Features

Figure 7. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)

Figure 8. Global Antisense & RNAi Therapeutics Market Share by Application: 2022 VS 2029

Figure 9. Oncology Case Studies

Figure 10. Cardiovascular Case Studies

Figure 11. Renal Case Studies

Figure 12. Neurodegenerative Case Studies

Figure 13. Respiratory Case Studies

Figure 14. Genetic Case Studies

Figure 15. Infectious Diseases Case Studies

Figure 16. Antisense & RNAi Therapeutics Report Years Considered

Figure 17. Global Antisense & RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029

Figure 18. Global Antisense & RNAi Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029

Figure 19. Global Antisense & RNAi Therapeutics Market Share by Region: 2022 VS 2029

Figure 20. Global Antisense & RNAi Therapeutics Market Share by Players in 2022

Figure 21. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2022)

Figure 22. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2022

Figure 23. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 24. North America Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

Figure 25. North America Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

Figure 26. North America Antisense & RNAi Therapeutics Market Share by Country (2018-2029)

Figure 27. United States Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 28. Canada Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 29. Europe Antisense & RNAi Therapeutics Market Size YoY (2018-2029) & (US$ Million)

Figure 30. Europe Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

Figure 31. Europe Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

Figure 32. Europe Antisense & RNAi Therapeutics Market Share by Country (2018-2029)

Figure 33. Germany Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 34. France Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 35. U.K. Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 36. Italy Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 37. Russia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 38. Nordic Countries Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 39. China Antisense & RNAi Therapeutics Market Size YoY (2018-2029) & (US$ Million)

Figure 40. China Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

Figure 41. China Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

Figure 42. Asia Antisense & RNAi Therapeutics Market Size YoY (2018-2029) & (US$ Million)

Figure 43. Asia Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

Figure 44. Asia Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

Figure 45. Asia Antisense & RNAi Therapeutics Market Share by Region (2018-2029)

Figure 46. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 47. South Korea Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 48. China Taiwan Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 49. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 50. India Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 51. Australia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 52. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Size YoY (2018-2029) & (US$ Million)

Figure 53. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Share by Type (2018-2029)

Figure 54. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Share by Application (2018-2029)

Figure 55. Middle East, Africa, and Latin America Antisense & RNAi Therapeutics Market Share by Country (2018-2029)

Figure 56. Brazil Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 57. Mexico Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 58. Turkey Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 59. Saudi Arabia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 60. Israel Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 61. GCC Countries Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

Figure 62. Glaxo Smith Kline Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 63. Sanofi Aventis / Genzyme Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 64. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 65. Arbutus Biopharma Ltd. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 66. Silence Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 67. Bio-Path Holdings Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 68. Calando Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 69. ICo Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 70. Quark Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 71. Rexhan Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 72. Biomarin/Prosensa Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 73. Regulus Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 74. Rxi Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 75. Silenseed Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 76. Dicerna Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 77. Sirnaomics Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023)

Figure 78. Bottom-up and Top-down Approaches for This Report

Figure 79. Data Triangulation

Figure 80. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmaceutical Autoclaves Market Insights, Forecast to 2029

120 Pages

Type: Report

Code: QYRE-Auto-9U9373

Sat Sep 23 00:00:00 UTC 2023

Add to Cart

Global Pterostilbene Market Insights, Forecast to 2029

120 Pages

Type: Report

Code: QYRE-Auto-38T8768

Sat Sep 23 00:00:00 UTC 2023

Add to Cart

Global Paclitaxel Market Insights, Forecast to 2029

120 Pages

Type: Report

Code: QYRE-Auto-37L8796

Sat Sep 23 00:00:00 UTC 2023

Add to Cart

Global Inosine Pranobex Market Insights, Forecast to 2029

120 Pages

Type: Report

Code: QYRE-Auto-3F9131

Sat Sep 23 00:00:00 UTC 2023

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions